The relationship between SARS-COV-2 RNA positive duration and the risk of recurrent positive

Abstract

Background The management of discharge COVID-19 patients with recurrent positive SARS-CoV-2 RNA is challenging. However, there are fewer scientific dissertations about the risk of recurrent positive. The aim of this study was to explore the relationship between SARS-COV-2 RNA positive duration (SPD) and the risk of recurrent positive. Methods This case–control multi-center study enrolled participants from 8 Chinese hospital including 411 participants (recurrent positive 241). Using unadjusted and multivariate-adjusted logistic regression analyses, generalized additive model with a smooth curve fitting, we evaluated the associations between SPD and risk of recurrent positive. Besides, subgroup analyses were performed to explore the potential interactions. Results Among recurrent positive patients, there were 121 females (50.2%), median age was 50 years old [interquartile range (IQR): 38–63]. In non-adjusted model and adjusted model, SPD was associated with an increased risk of recurrent positive (fully-adjusted model: OR = 1.05, 95% CI: 1.02–1.08, P = 0.001); the curve fitting was not significant (P = 0.286). Comparing with SPD < 14 days, the risk of recurrent positive in SPD > 28 days was risen substantially (OR = 3.09, 95% CI: 1.44–6.63, P = 0.004). Interaction and stratified analyses showed greater effect estimates of SPD and risk of recurrent positive in the hypertension, low monocyte count and percentage patients (P for interaction = 0.008, 0.002, 0.036, respectively). Conclusion SPD was associated with a higher risk of recurrent positive and especially SPD > 28 day had a two-fold increase in the relative risk of re-positive as compared with SPD < 14 day. What’s more, the risk may be higher among those with hypertension and lower monocyte count or percentage.

A unique dysregulation pattern of lipid metabolism and immune responses in patients with omicron SARS-CoV-2 recurrence

“…However, the mechanism leading to these re-positive cases is still unclear. 9 From this current study, our proteomic analysis demonstrated a unique pattern of lipid metabolism and immune response in Omi-Rec patients, which might spur further interest in exploring the association of lipid levels with inflammation in Omi-Rec patients and identifying a possible molecular link between lipoprotein metabolism, immune regulation and SARS-CoV-2 re-positive. The significant dysregulation proteins presented in our study may be valuable potential targets for identifying or treating Omicron-infected patients’ re-positive episodes.…”

Immunoglobulin Response and Prognostic Factors in Repeated SARS-CoV-2 Positive Patients: A Systematic Review and Meta-Analysis

“…The basic characteristics of the included articles are summarized in Table 1 . Out of the 34 included articles, 33 were from China [ 12 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 ] and 1 from Italy [ 30 ]. All of the included studies were conducted during the first wave of the COVID-19 pandemic.…”

Clinical features and corresponding immune function status of recurrent viral polymerase chain reaction positivity in patients with COVID-19 : A meta- analysis and systematic review

“…The literature search revealed a total of 4833 related articles. After removal of duplicates and application of the inclusion and exclusion criteria, 22 articles 5 – 26 remained. The detailed process of study screening is shown in Figure 1 .…”